Optimizing T-cell receptor gene therapy for hematologic malignancies.

Area of Science:

• Immunology
• Oncology
• Genetic Engineering

Background:

• Chimeric antigen receptor (CAR) T-cell therapy, particularly targeting CD19, has shown significant success in clinical trials for B cell malignancies.
• CARs recognize cell surface antigens, limiting their application to surface-expressed targets.

Purpose of the Study:

• To explore the potential of T-cell receptors (TCRs) for targeting intracellular tumor antigens, expanding therapeutic options beyond CARs.
• To address biological bottlenecks in mutation-specific T-cell therapy, including the need for high-avidity TCRs and potential safety concerns.
• To highlight the role of gene-editing technologies in developing universal, off-the-shelf T-cell therapies.

Main Methods:

• Review of recent advances in genetic engineering for T-cell therapy.
• Discussion of TCRs' ability to recognize intracellular antigens and target the cancer mutagenome.
• Analysis of challenges related to TCR affinity, peptide concentration, and potential cross-reactivity.
• Exploration of gene-editing tools like TALENs and CRISPR for TCR and HLA gene deletion.

Main Results:

• TCRs can target intracellular antigens, broadening the scope of T-cell therapy.
• High-avidity TCRs may be necessary for effective targeting of low-concentration mutant peptides.
• Artificially high-affinity TCRs may have suboptimal function at low peptide concentrations and pose safety risks due to cross-reactivity.
• Gene editing can remove endogenous TCR and HLA genes, reducing alloreactivity and immunogenicity.

Conclusions:

• TCR-based T-cell therapy offers expanded targeting capabilities for cancer treatment.
• Overcoming challenges in TCR affinity and specificity is crucial for effective and safe mutation-specific therapies.
• Gene editing advancements pave the way for developing "off-the-shelf" T-cell products for widespread patient use.